Acrivon Therapeutics Inc. announced that it will provide updates on its ongoing clinical programs, including interim data from the registrational-intent Phase 2b study of ACR-368 in endometrial cancer and initial clinical data from the Phase 1 study of ACR-2316, a WEE1/PKMYT1 inhibitor. The company will also discuss the planned confirmatory Phase 3 trial for ACR-368 and the nomination of a new preclinical development candidate from its AP3-driven cell cycle program. These updates will be shared via a press release at 7:30 a.m. ET, followed by a conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026. Results have not yet been presented and will be disclosed during the scheduled event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620423-en) on January 06, 2026, and is solely responsible for the information contained therein.